
Pharmacally
Psoriasis
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Psoriasis
Clinical TrialsInventisBio’s D-2570 Delivers Up to 90% PASI 75 Response in Psoriasis TrialInventisBio’s oral TYK2 inhibitor D-2570 demonstrated significant improvements in PASI 75, PASI 90 and PASI 100 responses in a Phase 2 trial involving patients with moderate-to-severe plaque psoriasis.…Fact-Checked
Clinical TrialsORKA-001 Sustains Deep Psoriasis Clearance Through Week 28 After Two DosesOruka Therapeutics reported that ORKA-001 sustained and deepened clinical responses in moderate-to-severe plaque psoriasis through Week 28.Fact-Checked
Clinical TrialsOruka Therapeutics Reports Strong 16-Week Results for ORKA-001 in PsoriasisInterim results from the EVERLAST-A trial show ORKA-001 achieved PASI 100 in 63.5% of patients at Week 16, with a safety profile comparable to placebo and potential for…Fact-Checked
Health TidingsAfter FDA Approval, J&J Shows Durable 52-Week ICOTYDE Results in PsoriasisNew 52-week data presented at AAD 2026 show ICOTYDE maintains strong skin clearance and a consistent safety profile, supporting its recent FDA approval in plaque psoriasis.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.